Member Info for beinthelead

You either believe in the product or not.

I’m more frustrated by the word ‘intraday’ than I am waiting for orders.

Sympathetic cross ramp :)

MrA - they won’t escalate dosing unless it adds value. Ie, feedback by year end will confirm if it adds value (works). The next year will be spent confirming just how much.

Thanks gmcc. Easy to forget we’re dosing patients very soon and genuinely close to extending peoples lives. Phenomenal.

Yes. This was the conclusion a few days ago.

I think we might find out today. Fingers crossed :)

Agreed. The specificity issue must be driving AS mad as it’s a blot to be honest. My money’s on the CE being accompanying by further validation numbers to improve that figure.

Fortunately, this isn’t an academic problem to solve, is a logistical one. People want holidays, the football, weddings, work place opening etc. We’d never achieve the ‘beyond zero’ target using PCR.

Perfect can’t be the enemy of good here. Reduce to a point of control. Our test is more than capable of that.

Thanks.

This process is about detecting infectious people, not detecting the protein. Our test is 100% sensitive in detecting potentially infectious people.

The requirement is for reducing the spread to a point where it’s controlled, using a quick, cheap device. This is a simple, disposable device that does that. No need to over complicate things.

Or just use two of ours. The solution has no requirement to be equitable, it’s just has to work.

Some don’t understand why he RNS’d the form submission over waiting for the endorsement - To explain to the fickle that he’s not the bottle neck, the regulators are. They’re outside of his control, always have been.

CE approval
Variant detection
Saliva switch
RTC involvement
Manufacturing monopolisation
Brexit impacts
Sample availability

Most of these delays are HMG implicated, hence why I believe we are key to their plans.

Ultimately, sell at near ATH’s or have some credibility and wait.

I don’t think it matters. They either want the test, or don’t.

The fact discussions are ongoing given they have validated LFT’s on the shelf, indicates he’s still wanting the best but can’t strike a deal.

Not good enough. Low sensitivity at low viral loads. Needs to be prof administered, needs kit, saliva shift etc.

I don’t Ndn, far from it. I see things objectively.

Simplex health, oh, I saw that. Check out their accompanying instructional video, stating 2-3cm.

I suggest removing negative emotion from any research. It’s clearly doesn’t help.

Flowflex is not 2cm, nor AN.

Even the made in UK thing, for me isn’t a USP as such. If the Chinese tests were mega, and matched our performance in use case, they’d be cheaper and produced in higher numbers. They’d sell better.

Thing is, they’ll never get close. The vague ‘nasal’ marketing is rife. Ndn had a pop the other day when I suggested the flow thing was NMT.

The other tests have missed the boat. Our selection of S protein (prevalence/stability in the anterior nasal site) and the Affimer sensitivity can’t be matched.

AffiDx is a unicorn.

Said many times before PL, there’s zero competition. That’s the beauty of this investment, and one I truly believe others don’t see. Well, they can’t as people sell :)

Swab their anterior nasal

Or that we’re not licensing the reagents to the Ukgov. They’ll be a customer, buying the test.

AffiDx will be supplied to UK, hence MHRA approval.

The US market is more likely to see AffiRx.

They will for whatever test they decide to use, hence the generic exemption. Performance aside, ours is easier to use by design :)